Aurobindo Pharma is currently trading at Rs. 678.00, up by 6.55 points or 0.98% from its previous closing of Rs. 671.45 on the BSE.
The scrip opened at Rs. 674.00 and has touched a high and low of Rs. 679.30 and Rs. 668.50 respectively. So far 40405 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 895.00 on 06-Oct-2016 and a 52 week low of Rs. 622.00 on 26-Dec-2016.
Last one week high and low of the scrip stood at Rs. 695.70 and Rs. 665.15 respectively. The current market cap of the company is Rs. 39370.29 crore.
The promoters holding in the company stood at 51.94%, while institutions and non-institutions held 35.07% and 13.00% respectively.
Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg. Aurobindo's Abacavir Sulfate and Lamivudine tablets are the AB rated generic equivalent of VIIV Healthcare Company's Epzicom tablets. The product is being launched immediately.
Abacavir Sulfate and Lamivudine tablets are indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection. The approved product has an estimated market size of $ 388 million for the twelve months ending December 2016 according to IMS.
This is the 108th ANDA (including 20 tentative approvals) approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 314 ANDA approvals (276 Final approvals including 16-from Aurolife Pharma LLC and 38 tentative approvals) from USFDA.